NEW YORK (GenomeWeb News) – Foundation Medicine and Agios Pharmaceuticals today announced a deal to develop diagnostics for the biopharmaceutical firm's drug candidates.

Under the terms of the deal, the partners seek to identify genomic alterations, which can be used to pick out those patients most likely to respond to Agios' new cancer metabolism inhibitors targeting tumors carrying mutations in either the IDH1 or IDH2 metabolic enzymes. Using this information, Foundation and Agios will then develop and potentially commercialize diagnostics for the drug candidates.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.